Evidence map›Paper›PMID 38379276›Full record

ArticleThe Kobe journal of medical sciences2024

Expression of EGFR and p16 in Squamous Cell Carcinoma of External Auditory Canal.

Yasuyuki Kajimoto, Hirotaka Shinomiya, Natsumi Uehara, Masanori Teshima, Takeshi Fujita, Akinobu Kakigi, Yoshinori Imamura, Naomi Kiyota, Daisuke Miyawaki, Ryohei Sasaki and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Kobe journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Yasuyuki KajimotoDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Hirotaka ShinomiyaDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Natsumi UeharaDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Masanori TeshimaDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Takeshi FujitaDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Akinobu KakigiDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Yoshinori ImamuraDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Naomi KiyotaDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Daisuke MiyawakiDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Ryohei SasakiDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, Japan.
Hidehito KimuraDepartment of Neurosurgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Ken-Ichi NibuDepartment of Otolaryngology-Head and Neck Surgery, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Kobe University Hospital · JPKobe University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The expression of EGFR and p16 in the external auditory canal squamous cell carcinoma (EACSCC) and their impacts on oncological outcomes were not well studied. Seventeen-one consecutive patients who were treated for EACSCC at Kobe University Hospital from 1995 to 2018 were enrolled in this study. The expression of EGFR, and p16 were evaluated and their impacts on oncological outcomes were statistically analyzed. Positive expression of EGFR was observed in 62 patients (87%). Strong positive expression of p16 were observed in 18 patients (32.4%), and weakly positive expression in 30 patients (42.3%), respectively. While the number of the patients with negative EGFR expression were limited, all the surgically treated patients with negative EGFR expression have been alive without disease. In the patients with T3 & T4a EACSCC, prognosis of the patients with positive p16 expression EACSCC tended to be better than those with negative p16 expression. These results suggest the clinical significance of EGFR and p16 expressions in the patients with advanced EACSCC to predict oncological outcomes.

Indexed as

Carcinoma, Squamous CellEar CanalErbB ReceptorsHumansPrognosisEGFR protein, humanErbB ReceptorsEar cancerEGFRKobe classificationp16Temporal bone

Identifiers

PMID38379276
PMCPMC11006239
OpenAlexW4394754674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.